brai

Samaritan's Alzheimer's Drug Caprospinol Suggests Brain May be Able to Heal From Alzheimer's Disease

Animal Study Confirms Caprospinol's (SP-233) Ability to Clear BrainPlaque and Empower Rat Brain Cells to Recover Memory Function In Vivo 'Proof of Concept' Study Proposes Direct CorrelationBetween Removing Beta Amyloid Plaque and Memory Recovery LAS VEGAS, July 10, 2007 (PRIME NEWSWIRE) -- SamaritanPharmaceuticals Inc. (AMEX:LIV), a developer of innovative drugs,is ple...

Stanford Researchers Find Brain Pathway of Depression in Rats

STANFORD, Calif.--(BUSINESS WIRE)--Jul 5, 2007 - Scientists' huntfor the cause of depression has implicated so many suspects andfound so many treatments with different mechanisms that thecondition remains an enigma. Now researchers at the StanfordUniversity School of Medicine have identified one unifyingprinciple that could explain how a range of causes and treatmentsfor depression converge...

Suven Life Sciences Presenting Pre-clinical data of their NCE’s SUVN-502 and SUVN-507at International Brain Research Organization (IBRO) 2007 World Congress of Neuroscience

HYDERABAD, India, July 5th, 2007 – Several datapresentations from Suven’s portfolio of investigationalneuroscience compounds will be presented at International Brain Research Organisation (IBRO) 2007 WorldCongress of Neuroscience to be held at Melbourne, Australia duringJuly 12-17, 2007. Scientists from Suven Discovery Research will be presenting newdata for 4 p...

Allos Therapeutics Reports Results for Phase 3 Enrich Study of Efaproxyn in Women With Brain Metastases Originating From Breast Cancer

Study Fails to Meet Primary Endpoint of Improvement in OverallSurvival WESTMINSTER, Colo., June 19, 2007 /PRNewswire-FirstCall/ --Allos Therapeutics, Inc. today announced top line results fromENRICH, the Company's pivotal Phase 3 study of Efaproxyn (efaproxiral) plus whole brain radiation therapy (WBRT) in womenwith brain metastases originating from breast cancer. The studyfailed to achi...

Stanford Researchers Track Human Stem Cells Transplanted Into Rat Brain

STANFORD, Calif.--(BUSINESS WIRE)--Jun 4, 2007 - Researchers at theStanford University School of Medicine have illuminated the pathtaken by human neural stem cells that were transplanted into thebrains of rats and mice, and found that the cells successfullynavigate toward areas damaged by stroke. The research group placed miniscule particles of iron insidestem cells to act as cellular bea...

Phase 2 Results for EntreMed's Panzem NCD Brain Cancer Study Presented at ASCO

Safety and Single-Agent Activity Support Development of Panzem(R)NCD as a Combination Therapy for Glioblastoma Multiforme ROCKVILLE, Md., June 05, 2007 /PRNewswire-FirstCall/ --EntreMed, Inc. , a clinical-stage pharmaceutical company developingtherapeutics for the treatment of cancer and inflammatory diseases,announces the presentation of results of a single-agent Phase 2study for Panzem(...

Merck at ASCO 2007: Encouraging Results in Progression-Free Survival in Patients With Aggressive Brain Tumors (glioblastoma) Using Cilengitide in Phase I/IIa Study

Abstracts: 2000, 2002 CHICAGO/DARMSTADT, Germany, June 4, 2007 – Results of aPhase I/IIa study presented today at the American Society ofClinical Oncology (ASCO) annual meeting in Chicago demonstrate theclinical activity of cilengitide in patients with newly diagnosedglioblastoma – a particularly aggressive form of brain tumor.Cilengitide i...

Positive Statistical Analysis from Synthetic Blood's Oxycyte Traumatic Brain Injury Trial Indicates Achievement of Primary Endpoint

COSTA MESA, Calif.--(BUSINESS WIRE)--May 15, 2007 - Synthetic BloodInternational, Inc. (OTCBB:SYBD) today announced positive data froma statistical analysis of its Phase IIa study with Oxycyte(TM) inpatients with traumatic brain injury. In line with preliminarystudy results announced in December 2006, statistical resultsconfirmed that the primary endpoint of increasing patients' oxygentensi...

Data Presented at AACR Meeting Show Peregrine's Bavituximab Equivalent Can Generate Curative Immune Responses as Part of a Vaccine-Like Regimen in Preclinical Models of Aggressive Brain Cancer

--Immunization with a Bavituximab Equivalent and Irradiated TumorCells Increased Long-Term Survival to 57% From 0% in Controls in aPreclinical Model of Brain Cancer-- LOS ANGELES and TUSTIN, Calif., April 18, 2007/PRNewswire-FirstCall/ -- Peregrine Pharmaceuticals, Inc. , aclinical stage biopharmaceutical company developing targetedmonoclonal antibodies for the treatment of cancer and hep...

UCLA: Lithium Builds Gray Matter in Bipolar Brains, UCLA Study Shows

Novel brain imaging technique suggests how lithium works as atherapeutic LOS ANGELES, April 12, 2007--Neuroscientists at UCLA have shownthat lithium, long the standard treatment for bipolar disorder,increases the amount of gray matter in the brains of patients withthe illness. The research is featured in the July issue of the journalBiological Psychiatry and is curren...

Fragile X, Down Syndromes Linked to Faulty Brain Communication, Stanford Researcher Finds

STANFORD, Calif.--(BUSINESS WIRE)--Apr 10, 2007 - The two mostprevalent forms of genetic mental retardation, Fragile X and Downsyndromes, may share a common cause, according to researchers atStanford University School of Medicine. The problem, a crippledcommunication network in the brain, may also be associated withautism. Although the genetics of the disorders are very different, theend...

Inotek Pharmaceuticals Announces Publication of Animal Data from Study of PARP Inhibition as Potential Preventative of Brain Injury Following Stroke

BEVERLY, Mass.--(BUSINESS WIRE)--Apr 10, 2007 - InotekPharmaceuticals Corporation announced today the publication in thejournal Stroke of preclinical animal data showing that theadministration of a poly(ADP-Ribose) polymerase (PARP) inhibitorhas a large protective effect on the survival of certain braincells following a stroke. PARP is a nuclear enzyme that directs therepair of damaged DNA...